Revenue
$11.51M
Fiscal year ended 2026-06-30Operating income
-$44.35M
Fiscal year ended 2026-06-30Free cash flow
-$34.98M
Fiscal year ended 2026-06-30Surrozen, Inc./DE (SRZN) reported revenue of $11.51M and net income of -$332.13M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Surrozen, Inc./DE’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $11.51M |
| Cost of revenue | Unavailable |
| Gross profit | Unavailable |
| Operating income | -$44.35M |
| Net income | -$332.13M |
| Research & development | $34.58M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | Unavailable |
| Income tax expense | Unavailable |
| Diluted EPS | Unavailable |
| Selling, general & administrative | Unavailable |
| General & administrative | $21.28M |
| Selling & marketing | Unavailable |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $102.04M |
| Total assets | $115.61M |
| Current assets | $109.40M |
| Total liabilities | $334.27M |
| Current liabilities | $9.01M |
| Total equity incl. NCI | -$218.66M |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | Unavailable |
| Accounts receivable | $5.00M |
| Goodwill | Unavailable |
| Long-term debt | Unavailable |
| Accounts payable | $1.07M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | -$34.76M |
| Capital expenditures | $222.00K |
| Investing cash flow | -$222.00K |
| Financing cash flow | $46.58M |
| Net change in cash | $11.60M |
| Stock-based compensation | $7.00M |
| Common dividends paid | Unavailable |
| Common share repurchases | Unavailable |
| Depreciation & amortization | $222.00K |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | -$34.98M |
| Gross margin | Unavailable |
| Operating margin | -385.3% |
| FCF margin | -303.9% |
| SBC / revenue | 60.9% |
| Current ratio | 12.14x |
| Revenue YoY growth | -8.8% |
| Net margin | -2885.3% |
| R&D / revenue | 300.4% |
| CapEx / revenue | 1.9% |
| Long-term debt / equity | Unavailable |
| Effective tax rate | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SRZN in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-06View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-11-07View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-09View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.